Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Adenosine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 known ✓ | P30542 | 3/20 | 0.80 |
| ▸ | ADORA3 known ✓ | P0DMS8 | 1/20 | 0.80 |
| ▸ | ADORA2A known ✓ | P29274 | 1/20 | 0.80 |
| ▸ | ADORA2B known ✓ | P29275 | 1/20 | 0.80 |
| ▸ | P2RY2 | P41231 | 4/20 | 0.82 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.80 |
| ▸ | DPP4 | P27487 | 1/20 | 0.80 |
| ▸ | MEN1 | O00255 | 1/20 | 0.80 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.80 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.80 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.80 |
| ▸ | GAPDH | P04406 | 1/20 | 0.80 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.80 |
| ▸ | STAT6 | P42226 | 1/20 | 0.80 |
| ▸ | PI4KA | P42356 | 1/20 | 0.80 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.80 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.80 |
| ▸ | DOT1L | Q8TEK3 | 1/20 | 0.80 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.80 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.80 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Adenosine SCHEMBL29796534 | 1.00 | P2RY2 (0.82) | P2RY2ADORA1SMN1; SMN2DPP4MEN1 | |
| Vidarabine SCHEMBL7170349 | 1.00 | P2RY2 (0.82) | P2RY2ADORA1SMN1; SMN2DPP4MEN1 | |
| Adenosine SCHEMBL1744580 | 1.00 | P2RY2 (0.82) | P2RY2ADORA1SMN1; SMN2DPP4MEN1 | |
| Adenosine SCHEMBL2210868 | 1.00 | P2RY2 (0.82) | P2RY2ADORA1SMN1; SMN2DPP4MEN1 | |
| Adenosine SCHEMBL459770 | 0.99 | P2RY2 (0.80) | P2RY2ADORA1SMN1; SMN2DPP4MEN1 | |
| Adenosine SCHEMBL29362201 | 0.99 | P2RY2 (0.80) | P2RY2ADORA1SMN1; SMN2DPP4MEN1 | |
| Adenosine SCHEMBL28296801 | 0.99 | P2RY2 (0.80) | P2RY2ADORA1SMN1; SMN2DPP4MEN1 | |
| Adenosine SCHEMBL459996 | 0.99 | P2RY2 (0.80) | P2RY2ADORA1SMN1; SMN2DPP4MEN1 | |
| Adenosine SCHEMBL28186074 | 0.99 | P2RY2 (0.80) | P2RY2ADORA1SMN1; SMN2DPP4MEN1 | |
| Adenosine SCHEMBL28240733 | 0.99 | P2RY2 (0.80) | P2RY2ADORA1SMN1; SMN2DPP4MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12589137-B2 | Compositions and methods for treating pathological calcification and ossification | YALE UNIVERSITY (US) | 2026-03-31 | — | — | US | disclosed |
| WO-2025213269-A1 | METHOD FOR CORRELATING ELECTRICAL PROPERTIES OF A TISSUE PORTION WITH ONE OR MORE METABOLIC CONDITION AND/OR PHYSIOLOGICAL PROPERTIES | 1625986 ONTARIO LIMITED (CA) | 2025-10-16 | — | — | WO | disclosed |
| WO-2025133360-A1 | COMPOSITION OF RAPAMYCIN, DIMETHYL SULFOXIDE AND WATER FOR USE IN THE TREATMENT OF STEATOSIS IN A LIVER GRAFT | Assistance Publique-Hôpitaux de Paris (FR) | 2025-06-26 | — | — | WO | disclosed |
| EP-4523757-A2 | COMPOSITIONS AND METHODS FOR TREATING PATHOLOGICAL CALCIFICATION AND OSSIFICATION | Yale University (US) | 2025-03-19 | — | — | EP | disclosed |
| EP-2956163-B1 | COMPOSITIONS FOR TREATING PATHOLOGICAL CALCIFICATION AND OSSIFICATION | UNIV YALE (US) | 2024-11-27 | — | — | EP | disclosed |
| US-20220152163-A1 | Compositions and Methods for Treating Pathological Calcification and Ossification | UNIV YALE (US) | 2022-05-19 | — | — | US | disclosed |
| US-11266722-B2 | Compositions and methods for treating pathological calcification and ossification | YALE UNIVERSITY (US) | 2022-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12589137-B2 | Compositions and methods for treating pathological calcification and ossification | ENPP1, ALPP, XPNPEP1 | ADORA1 836/4885ADORA3 1702/4885ADORA2A 1636/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.